Profile data is unavailable for this security.
About the company
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
- Revenue in USD (TTM)0.00
- Net income in USD-37.82m
- Incorporated2016
- Employees14.00
- LocationUnicycive Therapeutics Inc4300 El Camino Real, Suite 210LOS ALTOS 94022United StatesUSA
- Phone+1 (650) 384-0642
- Fax+1 (302) 655-5049
- Websitehttps://unicycive.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marker Therapeutics Inc | 3.31m | -14.05m | 36.55m | 8.00 | -- | 2.60 | -- | 11.04 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| ImmuCell Corp | 17.47m | -5.77m | 37.50m | 79.00 | -- | 1.49 | -- | 2.15 | -0.7454 | -0.7454 | 2.26 | 3.22 | 0.3941 | 1.96 | 8.86 | 221,160.40 | -13.03 | -5.16 | -14.19 | -5.53 | 22.15 | 40.04 | -33.05 | -12.64 | 0.8715 | -15.17 | 0.3238 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| NRX Pharmaceuticals Inc | 0.00 | -30.16m | 37.67m | 2.00 | -- | -- | -- | -- | -2.95 | -2.95 | 0.00 | -0.1398 | 0.00 | -- | -- | -- | -182.00 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -13.21m | 37.92m | 6.00 | -- | 10.06 | -- | -- | -1.22 | -1.22 | 0.00 | 0.1987 | 0.00 | -- | -- | 0.00 | -128.63 | -144.28 | -552.70 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 38.44m | -- | -- | 3.67 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -37.82m | 38.73m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Vyne Therapeutics Inc | 423.00k | -28.50m | 39.23m | 10.00 | -- | 0.4632 | -- | 92.73 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 39.34m | 8.00 | -- | 8.22 | -- | 36.55 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| IGC Pharma Inc | 1.22m | -14.15m | 39.65m | 61.00 | -- | 4.19 | -- | 32.60 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
| Quince Therapeutics Inc | 0.00 | -30.28m | 39.75m | 32.00 | -- | 0.5359 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 39.87m | 73.00 | -- | 1.45 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Sensei Biotherapeutics Inc | 0.00 | -31.92m | 39.88m | 27.00 | -- | 0.6818 | -- | -- | -1.20 | -1.20 | 0.00 | 2.33 | 0.00 | -- | -- | 0.00 | -36.55 | -47.03 | -39.39 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| Lexaria Bioscience Corp | 404.72k | -5.44m | 40.46m | 5.00 | -- | 5.97 | -- | 99.97 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 40.69m | 729.00 | -- | 0.3224 | -- | 0.236 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| OncoCyte Corp | 1.50m | -25.80m | 41.03m | 43.00 | -- | 1.24 | -- | 27.30 | -3.08 | -3.47 | 0.1869 | 3.10 | 0.0172 | -- | 1.20 | 34,953.49 | -28.41 | -35.11 | -31.93 | -39.71 | 27.48 | -- | -1,653.69 | -2,373.36 | -- | -146.07 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Data as of May 17 2024. Currency figures normalised to Unicycive Therapeutics Inc's reporting currency: US Dollar USD
29.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2023 | 3.47m | 9.99% |
| BVF Partners LPas of 31 Dec 2023 | 2.12m | 6.10% |
| Nantahala Capital Management LLCas of 05 Feb 2024 | 2.08m | 6.00% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 1.88m | 5.41% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 339.86k | 0.98% |
| Geode Capital Management LLCas of 31 Dec 2023 | 169.13k | 0.49% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 93.34k | 0.27% |
| Citadel Securities LLCas of 31 Dec 2023 | 35.42k | 0.10% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 35.04k | 0.10% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 34.09k | 0.10% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
